Second Oral SERD Shines in ER+ Breast Cancer

被引：3
|
作者：
Pob, Alissa
机构：
来源：
CANCER DISCOVERY | 2023年 / 13卷 / 03期
关键词：
D O I：
10.1158/2159-8290.CD-NB2023-0005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The first data from the phase II SERENA-2 trial look promising for the investigational oral selective estrogen receptor degrader camizestrant. Compared with standard fulvestrant, it significantly prolonged progression-free survival in postmenopausal women with advanced estrogen receptor-positive, HER2-negative breast cancer. Camizestrant also bested fulvestrant in subgroup analyses of patients who previously received a CDK4/6 inhibitor, had visceral metastases, or had ESR1 mutations. ©2023 American Association for Cancer Research.
引用
下载
收藏
页数：5
相关论文
共 50 条
  • [1] Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
    Hopcroft, Lorna
    Wigmore, Eleanor M. M.
    Williamson, Stuart C. C.
    Ros, Susana
    Eberlein, Cath
    Moss, Jennifer I.
    Urosevic, Jelena
    Carnevalli, Larissa S.
    Talbot, Sara
    Bradshaw, Lauren
    Blaker, Catherine
    Gunda, Sreeharsha
    Owenson, Venetia
    Hoffman, Scott
    Sutton, Daniel
    Jones, Stewart
    Goodwin, Richard J. A.
    Willis, Brandon S.
    Rooney, Claire
    DeBruin, Elza
    Barry, Simon T.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [2] Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
    Lorna Hopcroft
    Eleanor M. Wigmore
    Stuart C. Williamson
    Susana Ros
    Cath Eberlein
    Jennifer I. Moss
    Jelena Urosevic
    Larissa S. Carnevalli
    Sara Talbot
    Lauren Bradshaw
    Catherine Blaker
    Sreeharsha Gunda
    Venetia Owenson
    Scott Hoffmann
    Daniel Sutton
    Stewart Jones
    Richard J. A. Goodwin
    Brandon S. Willis
    Claire Rooney
    Elza C. de Bruin
    Simon T. Barry
    npj Breast Cancer, 9
  • [3] Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC).
    Bardia, Aditya
    Linden, Hannah M.
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Doroumian, Severine
    Celanovic, Marina
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] AMEERA-2: Phase 1 study of oral SERD amcenestrant (SAR439859) in Japanese women with ER+/HER2-advanced breast cancer
    Kotani, Haruru
    Tamura, Kenji
    Mukohara, Toru
    Yonemori, Kan
    Kawabata, Yumiko
    Nicolas, Xavier
    Tanaka, Tomoyuki
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2022, 33 : S470 - S470
  • [5] Estetrol for treatment of advanced ER+ breast cancer
    Schmidt, M.
    Honig, A.
    Verhoeven, C.
    Almstedt, K.
    Battista, M.
    Lenhard, H. G.
    Krijgh, J.
    Bennink, H. Coelingh
    CANCER RESEARCH, 2019, 79 (04)
  • [6] Estetrol for treatment of advanced ER+ breast cancer
    Verhoeven, Carole
    Schmidt, Marcus
    Hoenig, Arnd
    Duennebacke, Jan
    Dutman, Ellen
    Krijgh, Jan
    Bennink, Herjan Coelingh
    CANCER RESEARCH, 2018, 78 (04)
  • [7] Modeling ER+ breast cancer dormancy in mice
    Alexandra Le Bras
    Lab Animal, 2022, 51 : 285 - 285
  • [8] SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2-metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
    Chandarlapaty, S.
    Bardia, A.
    Lord, S.
    Linden, H.
    Pelekanou, V.
    Ternes, N.
    Ming, J.
    Boutet, V.
    Boitier, E.
    Gosselin, A.
    Lee, J. Sang
    Bele, W. Dos-Santos
    Protopopov, A.
    Celanovic, M.
    Bauchet, A-L.
    Campone, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S351 - S351
  • [9] Hippo signalling maintains ER expression and ER+ breast cancer growth
    Ma, Shenghong
    Wu, Zhengming
    Yang, Feng
    Zhang, Jianmin
    Johnson, Randy L.
    Rosenfeld, Michael G.
    Guan, Kun-Liang
    NATURE, 2021, 591 (7848) : E1 - E10
  • [10] Hippo signalling maintains ER expression and ER+ breast cancer growth
    Shenghong Ma
    Zhengming Wu
    Feng Yang
    Jianmin Zhang
    Randy L. Johnson
    Michael G. Rosenfeld
    Kun-Liang Guan
    Nature, 2021, 591 : E1 - E10
12345